Purchase Order 75N93021P01394

Award Date 9/14/21
Potential Completion Date 9/13/22
Potential Value $100K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Piscataway, NJ 08854, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $150,355.40 firm fixed price purchase order contract to Genscript USA Inc., a biotechnology company, for COVID-19 research services. The contract includes DNA synthesis, cloning, plasmid preparation, and antibody expression and purification to support the Vaccine Research Center's continued COVID-19 studies. The services are to be performed at the NIH facility...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a firm-fixed-price purchase order to Genscript USA Inc., a biotechnology company, for "EXPRESS PLASMID PREPARATION, EXPRESS MUTAGENESIS TARGET AND CLONEARK PLASMID PREPARATION" services. The $149,984.10 contract has a completion date of September 13, 2022 and does not have a set-aside designation. Genscript has provided similar services to support...
This federal contract award to Genscript USA Inc., a biotechnology company based in New Jersey, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). The $4,196.16 firm fixed-price purchase order is for gene synthesis services. Genscript, a for-profit organization, has a history of providing a wide range of molecular biology products and services to...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $13,459 purchase order to Genscript USA Inc. to provide custom subcloning and antibody sequencing services in support of the agency's biomedical research efforts. Work will be performed by Genscript in Piscataway, New Jersey over a three-month period concluding in early October 2023. The firm fixed price contract was awarded under an unidentified agency-wide...
This is a $1,147,346.00 firm fixed price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Genscript USA Inc., a for-profit biotechnology company. The contract is for customized biological services to support the development and testing of therapeutic antibody and vaccine candidates by NIAID's Vaccine Research Center. This includes services such as plasmid preparation, protein production, and gene to...
The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) awarded a firm fixed-price purchase order contract worth $66,835.54 to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is for the custom synthesis of genes and antibodies to support NIAID's biomedical research and public health initiatives. The contract was awarded on a sole-source basis under the authority of FAR 13.106-1 due to Genscript being the...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $250,000 firm fixed price purchase order to Genscript USA Inc. of Piscataway, New Jersey. The order is for gene production and protein expression services to support the agency's research efforts. Services include gene synthesis, cloning, plasmid preparation, and protein expression and purification. The sole source award was negotiated under the authority of 41 U.S.C. 1901(a)(1) based on...
This federal contract award to Genscript USA Inc. is for $182,897.61 to provide custom gene synthesis services to the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH) within the Department of Health and Human Services. The contract is a firm fixed-price purchase order with no set-aside designation, and the services include DNA synthesis, subcloning, and plasmid preparation to support HIV research being conducted at the NIH...
Genscript USA Incorporated will provide gene synthesis and vector ark cloning services to the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). Under the terms of a $12,108 firm fixed price purchase order, Genscript will deliver the requested products and services between September 2023 and September 2024. As the prime contractor, Genscript will leverage its expertise...
This federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, is for $20,000.00 in custom gene synthesis and expression services provided by Genscript USA Inc., a for-profit biotechnology company located in Piscataway, New Jersey. The contract has a firm fixed price and an ultimate completion date of July 31, 2024. While the original solicitation is not provided, the award likely...

This federal contract award to Genscript USA Inc., a biotechnology company, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services. The $100,320.00 firm-fixed-price purchase order is for the supply of CloNEARK plasmid preparation and Gene to Antibody products to support ongoing cellular and molecular research projects at NIAID's Laboratory of Immunogenetics. The award is not associated with a set-aside program and was issued as a sole-source contract after NIAID determined that Genscript was the only responsible source that could provide the required products and maintain the integrity of the research data. The contract has a period of performance ending on September 13, 2022.

Generated 3/22/24, 7:42 PM